Profound Medical

PROF

Market cap $164M

TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 1:20 p.m. Eastern Time in NYC.

To release full third quarter 2025 financial results on November 13th; conference call to follow To release full third quarter 2025 financial results on November 13th; conference call to follow

New program delivers TULSA Procedure's precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across Texas New program delivers TULSA Procedure's precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across Texas

TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets “BIG9” Conference on September 11, 2025 in New York City.

I am initiating Profound Medical Corp. at a Sell rating with a fair value of $2.9 per share due to financial concerns. TULSA-PRO shows promise for BPH and localized prostate cancer, but long-term efficacy and sales growth remain uncertain. Heavy reliance on share issuance, high SBC relative to revenue, and ongoing negative cash flow raise significant balance sheet risks.

Profound Medical Corp. (NASDAQ:PROF ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Arun Swarup Menawat - Chairman of the Board & CEO Mathieu Burtnyk - President Rashed Dewan - Chief Financial Officer Stephen Kilmer - Corporate Participant Investor Relations - Corporate Participant Thomas Tamberrino - Chief Commercial Officer Conference Call Participants Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division Douglas W. Loe - Leede Financial Inc., Research Division John Glenn McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Michael W.

Profound Medical (PROF) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.28 per share a year ago.

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.

TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting.